Cosela (trilaciclib) has been approved by the FDA to reduce the frequency of bone marrow suppression induced by chemotherapy for extensive-stage small cell lung cancer. Cosela, which acts by inhibiting cyclin-dependent kinase 4/6, is to be administered intravenously as a 30-minute infusion within four hours prior to the commencement of chemotherapy. The approval is based on the results of a trial that demonstrated a significant reduction in the duration and severity of neutropenia in addition to having a positive impact on red blood cell transfusions with its use. The adverse effects associated include among others fatigue, low levels of calcium, potassium, and phosphate and increased levels of aspartate aminotransferase.
Casimersen injection, an antisense oligonucleotide, has been approved by the FDA for the treatment of patients with Duchenne muscular dystrophy (DMD) and a rare DMD mutation. The approval is based on the results of a study that involved 43 participants with exon 45-skipping mutation of the DMD gene who received IV casimersen 30 mg/kg. The subjects showed an increase in the production of the muscle-fiber protein dystrophin. The adverse effects associated included upper respiratory tract infections, fever, joint and throat pain, headache and cough. The FDA also recommends monitoring kidney function in patients receiving this treatment owing to reports of renal toxicity observed in nonclinical studies.
A recent news release suggests that Moderna completed manufacturing a version of its vaccine to prevent infection by B.1.351, a variant first identified in South Africa. The company is sending doses of this mRNA-1273.351 booster vaccine to the National Institutes of Health (NIH) for evaluation in a clinical trial, the company announced today. The move is part of a strategy for addressing this and other variants of concern. Moderna will compare the safety and efficacy of different boosting options, including the new booster vaccine in development; combining the booster with the existing vaccine in a single, multivalent booster; or administering a lower dose of the existing vaccine as a booster shot.
The CDC’s Advisory Committee on Immunization Practices recommends shortening of rabies PrEP to a 2-dose vaccine schedule as opposed to the currently followed regimen of 3 doses. ACIP advises the 2-dose intramuscular vaccine on days 0 and 7 in immunocompetent persons of at least 18 years of age for whom rabies vaccine PrEP is indicated. ACIP has also put forward a recommendation of an intramuscular booster dose of the vaccine to be given after the initial 2-dose PrEP series between day 21 and 3 years.
A prescription-only, neuromuscular stimulation device, eXciteOSA, has been approved by the FDA to help reduce snoring and mild obstructive sleep apnea to be used during the day while the patient is awake. eXciteOSA through 4 electrodes, 2 located above the tongue and 2 below, delivers a series of electrical pulses with rest periods in between. The device is used 20 minutes once a day while awake for 6 weeks, and once a week subsequently. The adverse effects with the use of the device include among others excessive salivation, tongue or tooth discomfort, dental filling sensitivity and metallic taste.
According to recent reports, Dr Fauci suggests that "long COVID hat really is is post-acute sequelae of SARS-CoV-2 infection, which they are now referring to as 'PASC,' or P-A-S-C." He stressed that even patients with moderate cases of the infection can develop PASC. Symptoms include fatigue; gastrointestinal problems; "brain fog," or an inability to focus; depression; anxiety; sleep difficulties; and, in extreme cases, impaired lung capacity.
A new research suggests that long-term use of continuous positive airway pressure (CPAP) was associated with higher self-reported physical activity levels in adults with co-occurring obstructive sleep apnea (OSA) and cardiovascular disease. Researchers conducted a secondary analysis of the Sleep apnea cardiovascular endpoints (SAVE) trial that enrolled 2,687 adults aged 45-75 years old with OSA and confirmed CVD. In the study, participants were randomized to receive either CPAP plus usual care or usual care alone.
Women with a history of preeclampsia and gestational hypertension could have long-term complications of the heart. Women with such conditions are seen to have structural changes predominantly of the left ventricle a decade after childbirth, predisposing them to ischemic heart disease and heart failure. Researchers have found that the risk for such complications is more in women who along with having a history of hypertensive disorders during pregnancy also have high blood pressure at the time of assessment. In light of these findings, identifying women at risk and devising early interventional strategies are warranted to prevent heart disease from developing.
Early findings from research suggests that the modified cochlear implant placed in the inner ear of eight patients with BVH improved balance, movement, and quality of life in as little as 6 months. "All participants reported improved quality of life and being able to engage in activities they thought they would never be able to do again, and all participants agreed to continue using the device beyond their planned study period," researchers said.
A recent study by Pediatricians from Spain suggests that respiratory tract infections, immediately prescribing antibiotics may do more harm than good. The trial consisted of 436 children treated by primary care pediatricians. "Most RTIs are self-limiting, and antibiotics hardly alter the course of the condition, yet antibiotics are frequently prescribed for these conditions," the investigators wrote in Pediatrics. "Antibiotic prescription for RTIs in children is especially considered to be inappropriately high."